KLRA on Nasdaq

Kailera Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

TickerKLRA on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersWaltham, Massachusetts¹
Incorporated inDE²
Business address180 Third Avenue, 4Th Floor, Waltham, Ma 02451²
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Leadership

Who has led Kailera Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive officerRonald C. Renaud Jr. Apr 16, 2026 to now³
PresidentRonald C. Renaud Jr. Apr 16, 2026 to now³
Chief financial officerDouglas W. Pagan Apr 16, 2026 to now⁴

Board members and other officers (14)

Chief Commercial OfficerJamie Beth Coleman Apr 16, 2026 to now⁵
Chief People OfficerPaula Cloghessy Apr 16, 2026 to now⁶
Chief Medical OfficerScott M. Wasserman Apr 16, 2026 to now⁷
OfficerKathleen Tregoning Jul 8, 2026 to now⁸
Chief Technology OfficerNur Nicholson Sep 9, 2026 to now⁹
Board memberAdam Koppel Apr 16, 2026 to now¹⁰
Board memberAndrew T. Kaplan Apr 16, 2026 to now¹¹
Board memberChristopher Hite Apr 16, 2026 to now¹²
Board memberFrank Clyburn Apr 16, 2026 to now¹³
Board memberJohn F. Milligan Apr 16, 2026 to now¹⁴
Board memberMartin Mackay Apr 16, 2026 to now¹⁵
Board memberRonald C. Renaud Jr. Apr 16, 2026 to now³
Board memberYuting Liu Apr 16, 2026 to now¹⁶
General counselScott Akamine Apr 16, 2026 to now¹⁷

Timeline

Apr 16, 2026New chief executive Ronald C. Renaud Jr. becomes CEO³

Filings

62 filings to the SEC since October 2021: 2 quarterly reports, 3 major events, 42 insider forms, 5 large holders, 10 other. The latest 20:

Sep 9, 20264 EDGAR
Sep 9, 20263 EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 12, 202610-Q EDGAR
Aug 12, 20268-K EDGAR
Aug 5, 2026SCHEDULE 13G EDGAR
Jul 8, 20264 EDGAR
Jul 8, 20263 EDGAR
Jun 11, 20264 EDGAR
May 26, 202610-Q EDGAR
May 26, 20268-K EDGAR
Apr 23, 2026SCHEDULE 13D EDGAR
Apr 23, 2026SCHEDULE 13D EDGAR
Apr 22, 20264 EDGAR
Apr 22, 20264 OWNERSHIP DOCUMENT EDGAR
Apr 20, 20264 EDGAR
Apr 20, 20264 EDGAR
Apr 20, 20264 EDGAR
Apr 20, 20264 EDGAR

The 62 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Apr 20, 2026	RTW INVESTMENTS, LP10% owner	Buy	500,000	$16.00	$8.0M	Form 4
Apr 20, 2026	BCPE Perseus Investor, LP10% owner	Buy	8,398,438	$16.00	$134.4M	Form 4
Apr 20, 2026	Koppel AdamDirector	Buy	1,562,500	$16.00	$25.0M	Form 4
Apr 20, 2026	BCLS Fund IV Investments GP, LLC10% owner	Buy	1,562,500	$16.00	$25.0M	Form 4
Apr 20, 2026	Kaplan Andrew T.Director	Buy	8,398,438	$16.00	$134.4M	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

CANADA PENSION PLAN INVESTMENT BOARDSCHEDULE 13G, 1 filing Aug 14, 2026¹⁸
RTW INVESTMENTS, LPSCHEDULE 13G, 1 filing Aug 14, 2026¹⁹
Jiangsu Hengrui Pharmaceuticals Co., Ltd.SCHEDULE 13G, 1 filing Aug 5, 2026²⁰
BCLS Fund IV Investments, L.P.SCHEDULE 13D, 1 filing Apr 23, 2026²¹
BCPE Perseus Investor, LPSCHEDULE 13D, 1 filing Apr 23, 2026²²

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 99. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Bain Capital Investors LLC	26,255,581	$578.4M	12.0%	New
Bain Capital Life Sciences Investors, LLC	22,583,268	$497.5M	29.6%	New
Rtw Investments, LP	10,776,820	$237.4M	2.0%	New
Canada Pension Plan Investment Board	7,304,688	$160.9M	0.1%	New
Atlas Venture Life Science Advisors, LLC	5,171,282	$113.9M	12.9%	New
Fmr LLC	3,970,865	$87.5M	0.0%	New
BlackRock, Inc.	3,928,604	$86.5M	0.0%	New
Citadel Advisors LLC	3,240,787	$71.4M	0.0%	New
Adage Capital Partners Gp, L.l.c.	3,208,286	$70.7M	0.1%	New
Wellington Management Group Llp	2,919,110	$64.3M	0.0%	New
Royalty Pharma Sub-Manager, LLC	2,455,357	$54.1M	22.4%	New
Siren, L.L.C.	2,214,286	$48.8M	1.0%	New
Vanguard Capital Management LLC	1,693,958	$37.3M	0.0%	New
Vanguard Portfolio Management LLC	1,652,507	$36.4M	0.0%	New
Geode Capital Management, LLC	1,133,115	$25.0M	0.0%	New
Farallon Capital Management, L.l.c.	1,100,000	$24.2M	0.1%	New
Frazier Life Sciences Management, L.P.	1,100,000	$24.2M	0.5%	New
Trails Edge Capital Partners, LP	984,786	$21.7M	3.4%	New
UBS Group AG	972,683	$21.4M	0.0%	New
Jupiter Topco LLC	970,857	$21.3M	0.0%	New
Ameriprise Financial Inc	821,331	$18.1M	0.0%	New
Deep Track Capital, LP	700,000	$15.4M	0.2%	New
Eventide Asset Management, LLC	616,720	$13.6M	0.2%	New
Vestal Point Capital, LP	575,000	$12.7M	0.3%	New
Cormorant Asset Management, LP	550,000	$12.1M	0.6%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARKailera Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARKailera Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARRonald C. Renaud Jr., Chief executive officer
4
SEC EDGARDouglas W. Pagan, Chief financial officer
5
SEC EDGARJamie Beth Coleman, Chief Commercial Officer
6
SEC EDGARPaula Cloghessy, Chief People Officer
7
SEC EDGARScott M. Wasserman, Chief Medical Officer
8
SEC EDGARKathleen Tregoning, Officer
9
SEC EDGARNur Nicholson, Chief Technology Officer
10
SEC EDGARAdam Koppel, Board member
11
SEC EDGARAndrew T. Kaplan, Board member
12
SEC EDGARChristopher Hite, Board member
13
SEC EDGARFrank Clyburn, Board member
14
SEC EDGARJohn F. Milligan, Board member
15
SEC EDGARMartin Mackay, Board member
16
SEC EDGARYuting Liu, Board member
17
SEC EDGARScott Akamine, General counsel
18
SEC EDGARCANADA PENSION PLAN INVESTMENT BOARD SCHEDULE 13G on Kailera Therapeutics, Inc.
19
SEC EDGARRTW INVESTMENTS, LP SCHEDULE 13G on Kailera Therapeutics, Inc.
20
SEC EDGARJiangsu Hengrui Pharmaceuticals Co., Ltd. SCHEDULE 13G on Kailera Therapeutics, Inc.
21
SEC EDGARBCLS Fund IV Investments, L.P. SCHEDULE 13D on Kailera Therapeutics, Inc.
22
SEC EDGARBCPE Perseus Investor, LP SCHEDULE 13D on Kailera Therapeutics, Inc.